Literature DB >> 24777267

Renal Carcinoid Tumor Metastatic to the Uvea, Medial Rectus Muscle, and the Contralateral Lacrimal Gland.

Hayyam Kiratli1, Salih Uzun, Berçin Tarlan, Deniz Ateş, Dilek Ertoy Baydar, Figen Söylemezoğlu.   

Abstract

Renal carcinoid tumor is an exceedingly rare malignancy. A 57-year-old man with a renal carcinoid tumor discovered after metastasizing to intraocular and bilateral orbital structures is described. The patient presented with a blind painful OS and a right superotemporal subconjunctival mass. Imaging studies revealed a large left intraocular tumor, a mass in the left medial rectus muscle, and right lacrimal gland enlargement. The OS was enucleated, and incisional biopsies were performed from the other 2 lesions. Histopathological studies demonstrated metastatic neuroendocrine tumor with chromogranin and synaptophysin positivity. Systemic work up revealed a right renal mass and multiple hepatic metastatic lesions. Radical nephrectomy was performed, and octreotide, capecitabine, and temozolomide were administered. Removal of the primary tumor and the eye that had no prospect for useful vision and further treatment with octreotide, capecitabine, and temozolomide provided a disease progression-free period of 24 months and allowed the patient to function normally.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 24777267     DOI: 10.1097/IOP.0000000000000112

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  2 in total

1.  Clinical and Pathological Features of Primary Renal Well-Differentiated Neuroendocrine Tumor.

Authors:  Hua Jiang; He Zhang
Journal:  Onco Targets Ther       Date:  2022-05-27       Impact factor: 4.345

2.  Primary hepatic carcinoid tumor metastasizing to eyelid: A case report.

Authors:  Pedro J Davila; Jan C Ortiz-Rosario; Meliza Matinez; Ana C Toro; Jose J Echegaray; Maria Correa-Rivas; Armando L Oliver
Journal:  Am J Ophthalmol Case Rep       Date:  2019-07-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.